Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Innovative Medicines Revenue	54.35B	50.32B	Log In	Log In	Log In	Upgrade
Sandoz Revenue	-	-	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
United States Revenue (Post-Q2 2023 Reporting)	24.00B	21.15B	Log In	Log In	Log In	Upgrade
Europe Revenue (Post-Q2 2023 Reporting)	16.29B	15.56B	Log In	Log In	Log In	Upgrade
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting)	10.46B	10.02B	Log In	Log In	Log In	Upgrade
Canada and Latin America Revenue (Post-Q2 2023 Reporting)	3.60B	3.59B	Log In	Log In	Log In	Upgrade

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Europe Revenue (Pre-Q3 2023 Reporting)	-	-	Log In	Log In	Log In	Upgrade
United States Revenue (Pre-Q3 2023 Reporting)	-	-	Log In	Log In	Log In	Upgrade
Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting)	-	-	Log In	Log In	Log In	Upgrade
Canada and Latin America Revenue (Pre-Q3 2023 Reporting)	-	-	Log In	Log In	Log In	Upgrade

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Cardiovascular, Renal And Metabolic Revenue	9.76B	8.58B	Log In	Log In	Log In	Upgrade
Immunology Revenue	9.98B	9.29B	Log In	Log In	Log In	Upgrade
Neuroscience Revenue	5.66B	4.75B	Log In	Log In	Log In	Upgrade
Oncology Revenue	16.51B	14.74B	Log In	Log In	Log In	Upgrade
Established Brands Revenue	12.45B	12.96B	Log In	Log In	Log In	Upgrade

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Innovative Medicines Gross Profit	-	-	Log In	Log In	Log In	Upgrade
Sandoz Gross Profit	-	-	Log In	Log In	Log In	Upgrade
Corporate Gross Profit	-	-	Log In	Log In	Log In	Upgrade

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Innovative Medicines Operating Profit	-	-	Log In	Log In	Log In	Upgrade
Sandoz Operating Profit	-	-	Log In	Log In	Log In	Upgrade
Corporate Operating Profit	-	-	Log In	Log In	Log In	Upgrade

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Cosentyx Revenue	6.46B	6.14B	Log In	Log In	Log In	Upgrade
Gilenya Revenue	-	552.00M	Log In	Log In	Log In	Upgrade
Entresto Revenue	8.68B	7.82B	Log In	Log In	Log In	Upgrade
Tasigna Revenue	1.34B	1.67B	Log In	Log In	Log In	Upgrade
Lucentis Revenue	720.00M	1.04B	Log In	Log In	Log In	Upgrade

Updated Sep 30, 2025. Data Source: Fiscal.ai.